Related references
Note: Only part of the references are listed.Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
Thomas De Raedt et al.
CANCER CELL (2011)
Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2011)
Mammalian TOR signaling to the AGC kinases
Bing Su et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
C. Evangelisti et al.
LEUKEMIA (2011)
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
A. M. Martelli et al.
LEUKEMIA (2011)
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
Greg M. Delgoffe et al.
NATURE IMMUNOLOGY (2011)
IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylation
Xiaoduo Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mammalian target of rapamycin as a target in hematological malignancies
Kevin R. Kelly et al.
TARGETED ONCOLOGY (2011)
mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide
Won Jun Oh et al.
EMBO JOURNAL (2010)
Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways
Keunwook Lee et al.
IMMUNITY (2010)
Sin1-mTORC2 Suppresses rag and il7r Gene Expression through Akt2 in B Cells
Adam S. Lazorchak et al.
MOLECULAR CELL (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
CDK inhibitors: Cell cycle regulators and beyond
Arnaud Besson et al.
DEVELOPMENTAL CELL (2008)
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Tsuneo Ikenoue et al.
EMBO JOURNAL (2008)
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C
Valeria Facchinetti et al.
EMBO JOURNAL (2008)
PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival
Lana Bozulic et al.
MOLECULAR CELL (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng et al.
BLOOD (2007)
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1
David A. Guertin et al.
DEVELOPMENTAL CELL (2006)
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity
Estela Jacinto et al.
CELL (2006)
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s
Maria A. Frias et al.
CURRENT BIOLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
mTOR and cancer: reason for dancing at the crossroads?
GV Thomas
CURRENT OPINION IN GENETICS & DEVELOPMENT (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry
PL Tazzari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable
YH Min et al.
LEUKEMIA (2003)
Share Paper
